Hot off the press @TheLancet IPSOS phase 3 trial of 1st line Atezolizumab monotherapy vs single-agent chemotherapy in pts with advanced NSCLC ineligible for a platinum-containing chemo. Study showed better OS & quality of life with Atezo.
Hot off the press @TheLancet IPSOS phase 3 trial of 1st line Atezolizumab monotherapy vs single-agent chemotherapy in pts with advanced NSCLC ineligible for a platinum-containing chemo. Study showed better OS & quality of life with Atezo.